BMO Capital Sticks to Their Buy Rating for Cooper Co

By Carrie Williams

In a report issued on October 10, Joanne Wuensch from BMO Capital reiterated a Buy rating on Cooper Co (NYSE: COO), with a price target of $272. The company’s shares closed yesterday at $237.67.

According to, Wuensch is a 4-star analyst with an average return of 7.4% and a 69.5% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.

Currently, the analyst consensus on Cooper Co is Moderate Buy and the average price target is $262.14, representing a 10.3% upside.

In a report issued on October 10, Jefferies also reiterated a Buy rating on the stock with a $250 price target.

The company has a one-year high of $256.39 and a one-year low of $158.73. Currently, Cooper Co has an average volume of 449.2K.

Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is negative on the stock. Last month, Gary Petersmeyer, a Director at COO sold 3,977 shares for a total of $974,130.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

The Cooper Cos, Inc. operates as a medical device company. It operates through two business units: Cooper Vision and Cooper Surgical. The Cooper Vision business unit brings a refreshing perspective on vision care with a commitment to crafting quality lenses for contact lens wearers.